Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that drug sales for immunosuppressants in the treatment of ulcerative colitis (UC) will double from $36.5 million in 2002 to $73.4 million in 2012. According to the new Pharmacor study entitled Ulcerative Colitis, physicians believe that immunosuppressants should be used more frequently as maintenance therapies for UC, and earlier in the treatment regimen.

"The major trend between 2002 and 2012 will be the increasing use of immunosuppressant drugs in lieu of traditional 5-ASA therapy," said Kat Neumeyer, analyst at Decision Resources. "Experts state that physicians' increasing familiarity with long-term use of immunosuppressants for UC maintenance will allow these agents to displace 5-ASAs in moderate to severe UC cases."

The study also finds that, in 2012, estimated sales of TNF-alpha inhibitors will rank second only to those of aminosalicylates and account for 15% of the 2012 major-market total.

About Ulcerative Colitis

UC is a chronic, relapsing inflammation of the large intestine (colon) and/or rectum that afflicts a relatively small portion of the general population. In 2002, UC afflicted approximately 1.2 million people in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) -- a relatively small population, but one that represents significant market potential for agents with high efficacy coupled with an improved safety profile.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Ulcerative Colitis is an Immune and Inflammatory Disorders study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.,

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
marshall@dresources.com

Patent Expiries Will Stall Drug Sales For Benign Prostatic Hyperplasia Between 2007 And 2012

View Now